Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 15/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257468 | 0.89 | EGLN1 (0.48) | ABCG2ABCB1EGLN1 | |
| SCHEMBL24257630 | 0.88 | HPGD (0.39) | HPGDALDH1A1ABCG2ABCB1GAA | |
| SCHEMBL24257715 | 0.81 | EGLN1 (0.53) | HPGDALDH1A1GAARAB9ARXFP1 | |
| SCHEMBL24257467 | 0.81 | EGLN1 (0.50) | ABCG2EGLN1 | |
| SCHEMBL29248920 | 0.81 | ABCG2 (0.50) | ABCG2ABCB1RAB9A | |
| SCHEMBL24257722 | 0.80 | HPGD (0.48) | HPGDALDH1A1GAARAB9ARXFP1 | |
| SCHEMBL24257699 | 0.79 | HPGD (0.44) | HPGDALDH1A1GAARAB9ARXFP1 | |
| SCHEMBL24257571 | 0.78 | EGLN1 (0.45) | EGLN1 | |
| SCHEMBL24257683 | 0.76 | LMNA (0.50) | HPGDALDH1A1GAARAB9AEGLN1 | |
| SCHEMBL30546867 | 0.76 | LMNA (0.50) | HPGDALDH1A1GAARAB9AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | HPGD 109/4885ALDH1A1 1362/4885ABCG2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.